Skip to content
10-Q

Quarterly Report

VitaNova Life Sciences Corporation VNOV

0001683168-23-006437

← back to feed
Filed
Sep 14, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Sep 12, 2023 5.87M sh
Cash And Equivalents Q1 2024 · Jul 31, 2023 $0
Cash And Equivalents Q1 2024 · Apr 30, 2023 $8.73K
Current Liabilities Q1 2024 · Jul 31, 2023 $83.46K
Current Liabilities Q1 2024 · Apr 30, 2023 $67.94K
Total Liabilities Q1 2024 · Jul 31, 2023 $83.46K
Total Liabilities Q1 2024 · Apr 30, 2023 $67.94K
Current Assets Q1 2024 · Jul 31, 2023 $0
Current Assets Q1 2024 · Apr 30, 2023 $8.73K
Operating Income Q1 2024 · Jul 31, 2023 −$24.25K
Operating Income Q1 2024 · Jul 31, 2022 $2.13K
Total Assets Q1 2024 · Apr 30, 2023 $8.73K
Shares Diluted Q1 2024 · Jul 31, 2022 5.87M sh
Operating Cash Flow Q1 2024 · Jul 31, 2022 $6.78K
Stockholders Equity Q1 2024 · Jul 31, 2022 −$32.85K
Stockholders Equity Q1 2024 · Apr 30, 2022 −$34.99K
Eps Diluted Q1 2024 · Jul 31, 2022 $0.00
Eps Basic Q1 2024 · Jul 31, 2022 $0.00
Sga Expense Q1 2024 · Jul 31, 2022 $12.87K
Net Income Q1 2024 · Jul 31, 2022 $2.13K